A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

تجربة معشاة تقارن بين السيفتازيديم بمفرده والعلاج التوليفي بالمضادات الحيوية لدى مرضى السرطان المصابين بالحمى وقلة العدلات

Clicks: 738
ID: 110706
1986
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1 of 183 articles by views in The New England journal of medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
To assess the efficacy of single-agent therapy relative to standard combination antibiotic therapy for the initial management of fever and neutropenia in cancer patients, we conducted a randomized trial comparing ceftazidime alone with a combination of cephalothin, gentamicin, and carbenicillin. Of …
لتقييم فعالية العلاج الأحادي مقارنة بالعلاج التوليفي القياسي بالمضادات الحيوية للتدبير الأولي للحمى وقلة العدلات لدى مرضى السرطان، أجرينا تجربة معشاة تقارن بين استخدام السيفتازيديم بمفرده وتوليفة مكونة من السيفالوثين، والجنتاميسين، والكاربينيسيلين. ومن بين …
Reference Key
pa1986thea Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Pizzo PA;Hathorn JW;Hiemenz J;Browne M;Commers J;Cotton D;Gress J;Longo D;Marshall D;McKnight J;;
Journal The New England journal of medicine
Year 1986
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.